Evolution of the Average Target: BioNTech SE

Data source: BioNTech SE(BNTX)
Evolution of the Average Target - BioNTech SE

Evolution of the Target Price: BioNTech SE

Data source: BioNTech SE(BNTX)
Evolution of the Target Price - BioNTech SE

Changes in Analyst Recommendations: BioNTech SE

Data source: BioNTech SE(BNTX)
009.Qnix6J_vD4Rs40nb9qCLCv0e9sQSQRs_AXm-OM_GV4Y.Ex3BuN3cSu0A2jGDodbhXZh3w6xIGGpNYD_3V4q2HtAlO9W_x7d6sjWCIg~43adc4701c8f130b1750a8c13b2b51ee
10-09 BofA Adjusts Price Target on BioNTech to $114 From $122, Keeps Buy Rating MT
10-08 Argus Research Initiates Coverage on BioNTech SE With Hold Rating MT
10-07 BioNTech SE : Gets a Buy rating from Berenberg ZD
09-16 Berenberg Raises Price Target on BioNTech to $140 From $132, Keeps Buy Rating MT
09-16 BioNTech SE : UBS maintains a Buy rating ZD
09-16 BioNTech SE : Jefferies keeps its Buy rating ZD
09-16 BioNTech SE : Berenberg gives a Buy rating ZD
09-15 BioNTech SE : Jefferies maintains a Buy rating ZD
09-08 BMO Capital Downgrades BioNTech to Market Perform From Outperform, Adjusts PT to $105 From $128 MT
09-04 BioNTech SE : Goldman Sachs gives a Buy rating ZD
08-28 Germany's DAX Index Extends Gains; BioNTech Tumbles After Scrapping Cancer Vaccine Trial MT
08-26 BioNTech SE : Deutsche Bank reiterates its Buy rating ZD
08-20 Cancer vaccines finally garner the spotlight Alphavalue
08-20 BioNTech SE : Jefferies keeps its Buy rating ZD
08-05 Berenberg Bank Adjusts BioNTech SE Price Target to $132 From $140, Maintains Buy Rating MT
08-05 BIONTECH : Berenberg reiterates its Buy rating ZD
08-04 BIONTECH : Gets a Buy rating from Jefferies ZD
08-04 BIONTECH : Bernstein sticks Neutral ZD
08-04 BioNTech: Q2 miss, followed by a sales guidance downgrade Alphavalue
08-04 Wall Street Bets on the Magnificent Seven Again Zonebourse
07-14 Where would AI lead Pharma in the long run? Alphavalue
07-08 Morgan Stanley Adjusts Price Target BioNTech to $119 From $126, Maintains Overweight Rating MT
06-01 BIONTECH : Buy rating from Jefferies ZD
05-27 BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says MT
05-27 BIONTECH : From Neutral to Buy by UBS ZD

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - - -
+20.88%
+39.25%
+20.5%
+13.53%
+36.56%
+22.87%
+49.08%
+10.4%
+19.76%
Average +25.87%
Weighted average by Cap. +25.83%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
86.59EUR
Average target price
103.73EUR
Spread / Average Target
+19.79%
High Price Target
128.59EUR
Spread / Highest target
+48.50%
Low Price Target
67.87EUR
Spread / Lowest Target
-21.63%

Analyst Consensus Detail

Analyst consensus - BioNTech SE

Consensus revision (last 18 months)

Consensus revision (last 18 months) - BioNTech SE
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Ratings Surperformance© - BioNTech SE